Identifying therapeutic vulnerabilities of bone marrow-driven recurrence of ER+ breast cancer
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2210120
- Recipient
-
Regents Of The University Of Michigan UEI GNJ7BBP73WE9
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $1,169,999
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Ann Arbor, MI 48109, USA
Award details come from USAspending.gov.
About this award
The University of Michigan will receive $1,169,999 under a three-year Project Grant award from the Department of the Army Medical Command to identify therapeutic vulnerabilities of bone marrow-driven recurrence of ER+ breast cancer. The award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative solutions for battlefield medicine and investigations into medical issues.
Under this award, the University of Michigan will conduct research from September 2022 to September 2025 to explore therapeutic vulnerabilities of bone marrow microenvironments that drive recurrence of estrogen receptor-positive breast cancer after treatment. Insights from this research could help develop new therapeutic strategies to prevent recurrence in breast cancer patients.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $1,169,999 |
Quick answers
Who received award W81XWH2210120?
W81XWH2210120 was awarded to Regents Of The University Of Michigan by Medical Command (Department of the Army) on September 30, 2022.
How much is award W81XWH2210120 worth?
$1,169,999 has been obligated on W81XWH2210120.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award